| Name | melagatran |
|---|---|
| Synonyms | 2-[[(1R)-2-[(2S)-2-[(4-carbamimidoylphenyl)methylcarbamoyl]azetidin-1-yl]-1-cyclohexyl-2-oxoethyl]amino]acetic acid |
| Description | Melagatran is a direct and oral active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia[1]. Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion[2]. |
|---|---|
| Related Catalog | |
| Target |
Thrombin[1] |
| References |
| Density | 1.41g/cm3 |
|---|---|
| Molecular Formula | C22H31N5O4 |
| Molecular Weight | 429.51300 |
| Exact Mass | 429.23800 |
| PSA | 148.61000 |
| LogP | 2.33060 |
| Index of Refraction | 1.67 |